CRISPR Therapeutics CRSP - オプションチェーン | ADVFN

US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) オプション

CRISPR Therapeutics AG (CRSP)

44.40

-0.11

(-0.25%)

終値： 2月27日 6:00AM

44.85

0.45

( 1.01% )

取引時間後: 8:00AM

CRSP ライブオプションフロー

オプションコール

行使価格	買値	売値	前回の価格	中間価格	前日比	前日比 %	出来高	建玉	最終取引
40.00	3.80	4.70	4.80	4.25	0.00	0.00 %	0	70	-
40.50	3.20	5.20	0.00	4.20	0.00	0.00 %	0	0	-
41.00	3.40	3.90	3.74	3.65	0.00	0.00 %	0	112	-
41.50	2.60	3.70	7.80	3.15	0.00	0.00 %	0	5	-
42.00	2.50	2.75	3.70	2.625	0.80	27.59 %	10	82	02:34:09
42.50	2.05	2.30	9.74	2.175	0.00	0.00 %	0	9	-
43.00	1.60	1.85	1.88	1.725	0.09	5.03 %	80	206	04:05:24
43.50	1.30	1.50	2.60	1.40	0.00	0.00 %	0	132	-
44.00	1.00	1.20	1.70	1.10	0.43	33.86 %	11	58	03:21:21
44.50	0.75	0.95	0.60	0.85	-0.50	-45.45 %	13	16	05:35:49
45.00	0.60	0.70	0.65	0.65	-0.35	-35.00 %	107	259	05:56:29
45.50	0.40	0.80	0.80	0.60	0.23	40.35 %	4	47	02:57:29
46.00	0.30	0.45	0.38	0.375	-0.22	-36.67 %	106	145	05:52:56
46.50	0.20	0.40	0.40	0.30	0.00	0.00 %	17	30	03:38:19
47.00	0.15	0.30	0.25	0.225	-0.10	-28.57 %	90	162	05:03:27
47.50	0.10	0.30	0.30	0.20	0.02	7.14 %	18	33	05:52:08
48.00	0.10	0.25	0.10	0.175	-0.13	-56.52 %	78	140	05:59:06
48.50	0.05	0.20	0.20	0.125	0.02	11.11 %	18	37	02:18:28
49.00	0.05	0.20	0.08	0.125	-0.07	-46.67 %	28	94	04:03:00
49.50	0.05	0.20	0.13	0.125	0.00	0.00 %	0	49	-

個人投資家向けのプロ仕様のツール。

プレミアム

オプションプット

行使価格	買値	売値	前回の価格	中間価格	前日比	前日比 %	出来高	建玉	最終取引
40.00	0.09	0.05	0.09	0.07	0.00	0.00 %	0	99	-
40.50	0.00	0.75	0.00	0.00	0.00	0.00 %	0	0	-
41.00	0.36	0.10	0.36	0.23	0.00	0.00 %	0	34	-
41.50	0.05	0.15	0.05	0.10	-0.10	-66.67 %	6	24	02:38:33
42.00	0.10	0.20	0.18	0.15	-0.01	-5.26 %	13	60	05:41:15
42.50	0.15	0.25	0.24	0.20	-0.16	-40.00 %	3	8	05:51:08
43.00	0.25	0.40	0.43	0.325	0.00	0.00 %	0	197	-
43.50	0.40	0.50	0.13	0.45	-0.40	-75.47 %	1	24	02:36:42
44.00	0.40	0.65	0.60	0.525	-0.15	-20.00 %	148	484	05:55:00
44.50	0.80	0.95	1.08	0.875	0.08	8.00 %	17	32	05:35:49
45.00	1.10	1.25	1.50	1.175	0.12	8.70 %	3	209	05:36:04
45.50	1.45	1.65	1.55	1.55	0.00	0.00 %	0	27	-
46.00	1.85	2.00	1.00	1.925	-0.40	-28.57 %	6	316	02:13:45
46.50	2.25	2.50	1.20	2.375	-0.94	-43.93 %	1	57	02:20:48
47.00	2.60	2.90	2.05	2.75	-0.52	-20.23 %	6	533	03:07:51
47.50	3.10	3.40	1.40	3.25	0.00	0.00 %	0	108	-
48.00	3.50	3.80	3.37	3.65	-0.39	-10.37 %	3	265	04:22:04
48.50	3.90	4.50	3.30	4.20	0.00	0.00 %	0	29	-
49.00	4.40	4.80	3.31	4.60	-0.94	-22.12 %	2	168	01:37:18
49.50	4.70	5.60	5.52	5.15	3.36	155.56 %	1	34	05:40:27

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
CPOPPop Culture Group Company Ltd	US$ 1.38 (99.42%)	8.96M
ULYUrgent ly Inc	US$ 0.829 (97.38%)	5.9M
BLMZBloomZ Inc	US$ 0.4955 (37.72%)	6.75M
NIXXNixxy Inc	US$ 2.1199 (34.17%)	7.78M
ROOTRoot Inc	US$ 114.00 (15.49%)	108k
SYTASiyata Mobile Inc	US$ 3.16 (-24.22%)	487.72k
SPGCSacks Parente Golf Inc	US$ 0.56 (-23.51%)	1.41M
DMRCDigimarc Corporation	US$ 21.70 (-19.75%)	30.3k
PITAHeramba Electric PLC	US$ 0.5529 (-19.69%)	1.49M
ONVOOrganovo Holdings Inc	US$ 0.701 (-17.53%)	2.5M
NVDANVIDIA Corporation	US$ 132.4099 (0.86%)	37.87M
CPOPPop Culture Group Company Ltd	US$ 1.38 (99.42%)	8.96M
NIXXNixxy Inc	US$ 2.1103 (33.56%)	7.78M
BLMZBloomZ Inc	US$ 0.4955 (37.72%)	6.75M
CLEUChina Liberal Education Holdings Ltd	US$ 0.063 (-15.21%)	6.55M

jondoeuk

jondoeuk 5日前

Looks pretty bullish for Casgevy https://www.businesswire.com/news/home/20250221469479/en/bluebird-bio-Announces-Definitive-Agreement-to-be-Acquired-by-Carlyle-and-SK-Capital

TechandBio

TechandBio 1週前

Added a chunk today to my stash average is now 42.00

$CRSP

TechandBio

TechandBio 1週前

Nice pre market action!

Very deep pipeline with a mega partner VRTX

$CRSP

TechandBio

TechandBio 2週前

Starting to turn the corner now!

Glad I re-loaded the low 40's

$CRSP

jondoeuk

jondoeuk 1月前

Anticipated 2025 milestones https://www.globenewswire.com/news-release/2025/01/13/3008308/0/en/CRISPR-Therapeutics-Highlights-Strategic-Priorities-and-Anticipated-2025-Milestones.html

jondoeuk

jondoeuk 1月前

Link to the webcast https://jpmorgan.metameetings.net/events/healthcare25/sessions/58421-crispr-therapeutics/webcast/general_signin?gpu_only=true&kiosk=true+%5Bjpmorgan.metameetings.net%5D

jondoeuk

jondoeuk 2月前

They will present at the 43rd Annual J.P. Morgan Healthcare Conference (Jan 14, at 2:15 PM PST).

PonkenPlonken

PonkenPlonken 3月前

jondoeuk

jondoeuk 3月前

The PR https://www.globenewswire.com/news-release/2024/12/09/2993974/0/en/CRISPR-Therapeutics-Presents-Data-at-the-2024-American-Society-of-Hematology-ASH-Annual-Meeting.html

Poster https://ir.crisprtx.com/static-files/12114290-21a6-4544-9cb7-de4fe2852e94

PonkenPlonken

PonkenPlonken 3月前

Neglected ugly duckling. $NTLA, $VERV & $CRBU now do trials outside of the US.... Maybe sentiment change is on the horizon -- see below

"The CBER director also apologized for “mistakes” in how the FDA handled early work for in vivo gene therapies, which “led to offshoring of some of the trials.”"
https://endpts.com/fda-vaccine-chief-peter-marks-pledges-to-stay-as-long-as-hes-welcome/#:~:text=The%20CBER%20director%20also%20apologized,%E2%80%9Cit%20is%20really%20important.%E2%80%9D

CHEAP CHEAP
SRPT and BMS announcing nice CRISPR deals with ARWR and PRME should help this too!

jondoeuk

jondoeuk 3月前

CTX130 data in R/R T-cell lymphomas (peripheral T-cell lymphoma or cutaneous T-cell lymphoma) https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00508-4/abstract

The ORR was 46.2%. Of those treated at DL3 and higher, the ORR was 51.6%.

PonkenPlonken

PonkenPlonken 3月前

so so so undervalued and misunderstood i believe...... frankly just cheap
https://x.com/RNAiAnalyst/status/1859876294487363651

jondoeuk

jondoeuk 3月前

They now have the ability to put in eight to nine edits. So it is a single cassette that expresses the CAR, can express a cytokine and has an shRNA-like approach to knock down genes. So there's no theoretical limit as to the number of edits, but there may be marginal utility beyond a certain point.

Hopefully, they look to improve donor selection, cell selection and manufacturing, as all could increase efficacy.

jondoeuk

jondoeuk 4月前

ASH abstract https://ash.confex.com/ash/2024/webprogram/Paper203563.html

jondoeuk

jondoeuk 4月前

Q3 business update and financial results https://www.globenewswire.com/news-release/2024/11/05/2974996/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2024-Financial-Results.html

Monksdream

Monksdream 4月前

Monksdream

Monksdream 4月前

jondoeuk

jondoeuk 4月前

OT: In this Dr. Urnov, PhD, laid out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies https://www.liebertpub.com/doi/10.1089/crispr.2024.0082

TechandBio

TechandBio 5月前

CRSP will climb tremendously over the years.
SMMT went from $1.00-30.00+ this year cancer drug superior to Mercks Keytruda
ICCM company being over looked that kills cancers by freezing them 97% non recurrence rate for breast cancer after 5 years and superior data to lung cancer safe cryoblation is done in less than hour.
https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

Monksdream

Monksdream 5月前

Buy range again thanks a bunch

Monksdream

Monksdream 5月前

Buy range again thanks a bunch

OldAIMGuy

OldAIMGuy 5月前

Hi MD,
Here's a little longer view:

This might also be a cyclical low here. But, most of 2024 has shown severe distribution of shares until about the last month. That, at least, seems to be flattening out.
Best wishes,
OAG

Monksdream

Monksdream 5月前

CRSP trend since February remains bearish

jondoeuk

jondoeuk 7月前

Q2 results https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200100452.html

lambchops

lambchops 7月前

Hey Monk, Hopefully you bought some shares on Friday@ Sold at 10% discount!

LC

CRISPR!!!

Monksdream

Monksdream 7月前

TechandBio

TechandBio 8月前

Crispr added some $120 Vertical debit spreads in 2026

$CRSP

axelvento

axelvento 9月前

I agree.....solid company$$$$$$$$

Monksdream

Monksdream 9月前

It may take some time for CRSP returns to a $200 price tag
The same could be said for hundreds of other stocks that soared during Covid mania
Since then the stock has rallied from low points
With all that money the company has to do incredible things with its biotechnology the stock isn’t going to zero

axelvento

axelvento 10月前

Strong balance sheet with approximately $2.1 billion in cash, cash equivalents, and marketable securities as of March 31, 2024

https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000059.html

jondoeuk

jondoeuk 10月前

(OT): A new AI paper from Princeton and Stanford https://www.biorxiv.org/content/10.1101/2024.04.25.591003v2.full

CRISPR-GPT demonstrated a marked improvement in gene-editing experiments, increasing the accuracy of target gene modifications by up to 30% compared to conventional methods. In validation tests, it achieved a specificity rate exceeding 95%, with a significant reduction in off-targets. The system also reduced the time required to design and plan experiments by approximately 40%, streamlining the workflow for researchers.

jondoeuk

jondoeuk 10月前

Business Update and Q1 Financial Results https://uk.finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000300.html

jondoeuk

jondoeuk 10月前

Highlights (plus new programs utilising in vivo gene editing) https://finance.yahoo.com/news/crispr-therapeutics-highlights-asgct-oral-110000066.html

jondoeuk

jondoeuk 10月前

https://www.globenewswire.com/news-release/2024/04/22/2867236/0/en/CRISPR-Therapeutics-to-Present-Oral-Presentation-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-2024-Annual-Meeting.html

EDIT is also pursuing myocilin-related glaucoma https://www.globenewswire.com/news-release/2024/04/22/2867244/0/en/Editas-Medicine-to-Present-Pre-clinical-Data-Demonstrating-Progression-of-in-vivo-Medicines-Pipeline-at-the-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html

OldAIMGuy

OldAIMGuy 11月前

StockCharts 3 year history with 20% ZigZag reversals................

CRSP seems to be suffering from lack of 'sponsorship' in that the stock has not shown "accumulation" trend along with the price rally since last year's October Low. There's been volume, but not accumulation bias.

Best wishes,
OAG

OldAIMGuy

OldAIMGuy 11月前

Hi MD,
CRSP is now down around 1/3 from its February high. The price is where I usually start to accumulate more shares.

Best wishes,
OAG

Monksdream

Monksdream 11月前

jondoeuk

jondoeuk 11月前

Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-american-society-120000624.html

Monksdream

Monksdream 1年前

CRSP new 52 week high

Monksdream

Monksdream 1年前

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Monksdream

Monksdream 1年前

CRSP new 52 week high

Monksdream

Monksdream 1年前

CRSP new 52 week high

jondoeuk

jondoeuk 1年前

They entered into an investment agreement for the sale of ~$280 million of its shares to a select group of institutional investors in a registered direct offering, at $71.5 apiece. The financing is being led by EcoR1 Capital and SR One with participation from existing investors and a healthcare specialist investor https://finance.yahoo.com/news/crispr-therapeutics-announces-280-million-133000932.html

jondoeuk

jondoeuk 1年前

EU approval https://finance.yahoo.com/news/european-commission-approves-first-crispr-065900771.html

Monksdream

Monksdream 1年前

Didn’t tank like BLUE
Recovered

More analysis from Nanolyze

Monksdream

Monksdream 1年前

So there has been some discussion since my last post
More in this podcast

jondoeuk

jondoeuk 1年前

Around two months ahead of expectations https://www.globenewswire.com/news-release/2024/01/16/2810298/0/en/CRISPR-Therapeutics-Announces-U-S-Food-and-Drug-Administration-FDA-Approval-of-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Transfusion-Dependent-Beta-Thalassemia.html

jondoeuk

jondoeuk 1年前

Strategic Priorities and 2024 Outlook https://finance.yahoo.com/news/crispr-therapeutics-highlights-strategic-priorities-120000043.html

jondoeuk

jondoeuk 1年前

Webcast link https://jpmorgan.metameetings.net/events/healthcare24/sessions/49607-crispr-therapeutics-inc/webcast/general_signin?gpu_only=true&kiosk=true

jondoeuk

jondoeuk 1年前

Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-42nd-annual-133000024.html

CRISPR Therapeutics

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約